

Protocol

Computed Tomography Perfusion Imaging of the Brain

(60149)

Medical Benefit		Effective Date: 01/01/16	Next Review Date: 03/21
Preauthorization	Yes	Review Dates: 11/14, 11/15, 11/16, 03/17, 03/18, 03/19, 03/20	

Preauthorization is required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: • With acute stroke who are being evaluated for thrombolysis	Interventions of interest are: • Computed tomography perfusion imaging	Comparators of interest are: • Standard workup without computed tomography perfusion imaging	Relevant outcomes include: • Overall survival • Test accuracy • Symptoms • Morbid events • Functional outcomes
Individuals: • With acute anterior large-vessel stroke who are being evaluated for mechanical embolectomy	Interventions of interest are: • Computed tomography perfusion imaging	Comparators of interest are: • Standard workup without computed tomography perfusion imaging	Relevant outcomes include: • Overall survival • Test accuracy • Symptoms • Morbid events • Functional outcomes
Individuals: • With acute stroke who are being evaluated for prognosis	Interventions of interest are: • Computed tomography perfusion imaging	Comparators of interest are: • Standard workup without computed tomography perfusion imaging	Relevant outcomes include: • Overall survival • Test accuracy • Symptoms • Morbid events • Functional outcomes
Individuals: • With subarachnoid hemorrhage and cerebral vasospasm	Interventions of interest are: • Computed tomography perfusion imaging	Comparators of interest are: • Clinical evaluation	Relevant outcomes include: • Overall survival • Test accuracy • Symptoms • Morbid events • Functional outcomes
Individuals: • With brain tumors	Interventions of interest are: • Computed tomography perfusion imaging	Comparators of interest are: • Magnetic resonance imaging	Relevant outcomes include: • Test accuracy • Symptoms • Morbid events • Functional outcomes

DESCRIPTION

Computed tomography perfusion (CTP) imaging provides an assessment of cerebral blood flow that may help

identify ischemic regions of the brain. This technology is proposed to aid treatment decisions in patients being evaluated for acute ischemic stroke, subarachnoid hemorrhage, cerebral vasospasm, brain tumors, and head trauma.

SUMMARY OF EVIDENCE

ACUTE STROKE

For individuals who have acute stroke who are being evaluated for thrombolysis who receive CTP imaging, the evidence includes a systematic review with meta-analysis, a randomized controlled trial (RCT), and cohort studies. Relevant outcomes are overall survival (OS), test accuracy, symptoms, morbid events, and functional outcomes. One potential area of benefit is greater individualization of therapy for acute stroke by better defining at-risk ischemic areas that may benefit from thrombolysis. Evidence from nonrandomized comparative studies has suggested that outcomes after thrombolysis are better in patients who have target mismatch on perfusion imaging than in patients without target mismatch and that patients with target mismatch treated after a three-hour time window have outcomes similar to patients treated within three hours. However, the therapeutic changes that would be associated with identifying specific target mismatch pattern on CTP are not well-defined. Additionally, although available evidence from the RCT suggests some modest benefit for acute stroke patients who receive CTP or magnetic resonance imaging and receive alteplase up to nine hours post-stroke, the overall net health outcome is unclear because there was also a lack of significant benefit on the secondary outcome of functional improvement and a trend toward increased risk of symptomatic intracranial hemorrhage and there were important limitations in relevance and potential limitations in statistical power. Therefore, RCTs are needed to determine with greater certainty whether a strategy employing CTP imaging improves health outcomes compared with traditional strategies for the treatment of acute stroke. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have acute anterior large-vessel stroke who are being evaluated for mechanical embolectomy who receive CTP imaging, the evidence includes RCTs and cohort studies. Relevant outcomes are OS, test accuracy, symptoms, morbid events, and functional outcomes. CTP is one of the several approaches used in acute stroke to define viable ischemic tissue better and therefore identify patients who might benefit from mechanical endovascular intervention. Alternative methods of patient selection for mechanical embolectomy have included time from stroke onset, multiphase computed tomography angiography, or Alberta Stroke Program Early CT Score. Three RCTs showed improved outcomes with mechanical embolectomy when patients were selected based on CTP results within six hours, at six to 16 hours, and at six to 24 hours. The evidence is sufficient to quantitatively determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have acute stroke who are being evaluated for prognosis who receive CTP imaging, the evidence includes retrospective analyses of large randomized trials. Relevant outcomes are OS, test accuracy, symptoms, morbid events, and functional outcomes. Retrospective analysis of data from the MR CLEAN and DUST trials have found that the ischemic core detected on CTP imaging was predictive of functional outcomes. However, analysis of data from the DUST study found no improvement in a prediction model when CTP imaging was added to a basic model that used only patient characteristics and non-contrast computed tomography. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUBARACHNOID HEMORRHAGE

For individuals who have subarachnoid hemorrhage and cerebral vasospasm who receive CTP imaging, the evidence includes asystematic review with meta-analysis and a cohort study. Relevant outcomes are OS, test accuracy, symptoms, morbid events, and functional outcomes. CTP imaging is being evaluated for the diagnosis of vasospasm and delayed cerebral ischemia following aneurysmal SAH. One prospective study showed a qualitative measure of cerebral blood flow to have 93% accuracy for the detection of delayed cerebral ischemia, with

lower accuracy for cerebral blood volume. Prospective trials are needed to determine whether CTP imaging in patients with aneurysmal SAH leads to the early identification of patients at high-risk for vasospasm or delayed cerebral ischemia, alters treatment decisions, and improves health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

BRAIN TUMORS

For individuals who have brain tumors who receive CTP imaging, the evidence includes studies on diagnostic accuracy. Relevant outcomes are test accuracy, symptoms, morbid events, and functional outcomes. For indications such as brain tumors and head trauma, the data on CTP imaging is limited. One study assessed the diagnostic accuracy of CTP imaging to differentiate high-grade from low-grade gliomas. Prospective studies in an appropriate population of patients are needed to evaluate the sensitivity and specificity of CTP glioma grading, with a histopathologic assessment of tumors as the independent reference standard. One prospective study performed a receiver operating characteristic curve analysis to evaluate the diagnostic accuracy of volume perfusion computed tomography. This is the first report using volume perfusion computed tomography to differentiate gliomas; therefore, replication of these findings in an independent sample of patients is needed as well as clarification of the clinical utility of this information. Studies showing the consistency in the thresholds used are needed as are studies showing improvement in health outcomes with CTP imaging. No recent reports on the use of CTP imaging for the evaluation of brain tumors have been identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Computed tomography perfusion imaging may be considered **medically necessary** to select patients with anterior large-vessel stroke for mechanical embolectomy.

Computed tomography perfusion imaging of the brain is considered **investigational** for all other indications.

POLICY GUIDELINES

Selection criteria for the EXTEND-IA trial included patients with an anterior large-vessel stroke who: were receiving tissue plasminogen activator (tPA); were able to receive endovascular therapy within six hours of stroke onset; were functionally independent prior to the stroke; and had evidence of salvageable brain tissue and an ischemic core with a volume of less than 70 mL on CTP imaging.

BACKGROUND

ACUTE STROKE

The goal of acute stroke thrombolytic treatment is to rescue the ischemic penumbra, an area of the brain that surrounds the infarct core and is hypoperfused but does not die quickly. Multimodal computed tomography (CT) and magnetic resonance imaging (MRI) can be used to assess the cerebral parenchyma, vasculature, and tissue viability in the acute ischemic stroke setting and are used to detect ischemic tissue and exclude hemorrhage and other conditions that mimic acute cerebral ischemia.

Non-contrast CT is used to rule out intracranial hemorrhage, tumor, or infection. Diffusion-weighted MRI is used to identify acute infarction, and a gradient-recalled echo sequence is used to exclude intracerebral hemorrhage.

CT angiography and magnetic resonance angiography are used to evaluate intra- and extracranial vasculature to detect the vascular occlusion and potentially guide therapy (e.g., intravenous thrombolysis or mechanical thrombectomy).

The approved therapy, use of an intravenous tissue plasminogen activator, requires only a non-contrast CT scan to exclude the presence of hemorrhage (a contraindication to use of the drug). Current guidelines are to administer tissue plasminogen activator within the first three hours after an ischemic event, preceded by a CT scan. Many patients, however, do not present to the emergency department within the three-hour window, and thrombolysis carries a risk of intracranial hemorrhage. Thus, more sophisticated imaging may be needed to select the proper use of intra-arterial thrombolysis or mechanical thrombectomy in patients who present more than three hours after an ischemic stroke. Perfusion imaging is also being evaluated in the management of other neurologic conditions, such as subarachnoid hemorrhage and head trauma.

The potential utility of perfusion imaging for acute stroke is as follows:

- identification of brain regions with extremely low cerebral blood flow, which represent the core
- identification of patients with at-risk brain regions (acutely ischemic but viable penumbra) that may be salvageable with successful intra-arterial thrombolysis beyond the standard three-hour window
- triage of patients with at-risk brain regions to other available therapies, such as induced hypertension or mechanical clot retrieval
- decisions regarding intensive monitoring of patients with large, abnormally perfused brain regions
- biologically based management of patients who awaken with a stroke for which the precise time of onset is unknown.

Additional potential uses of CT perfusion (CTP) in acute stroke may include the following:

- detection and differential diagnosis (e.g., excluding stroke mimics such as a transient ischemic attack, complex migraine, seizure, conversion disorders, hypoglycemia, brain tumors)
- determination of stroke subtype
- determination of stroke extent, including additional vascular territories at risk
- identification of patients at high early risk of stroke following a transient ischemic attack
- determining the need for blood pressure management
- establishing prognosis.

Similar information can be provided by CT and MRI regarding infarct core and penumbra. However, multimodal CT has a short protocol time (five to six minutes) and, because it can be performed with any modern CT equipment, is more widely available in the emergency department setting. CTP is performed by capturing images as an iodinated contrast agent bolus passes through the cerebral circulation and accumulates in the cerebral tissues. (Older perfusion methodologies such as single-photon emission CT and xenon-enhanced CT scanning use a diffusible tracer.) The quantitative perfusion parameters are calculated from density changes for each pixel over time with the commercially available deconvolution-based software, in which cerebral blood flow is equal to regional cerebral blood volume divided by mean transit time. CT angiography and CTP imaging require ionizing radiation and iodinated contrast. It is estimated that typical CTP imaging deposits a slightly greater radiation dose than a routine unenhanced head CT ($\gg 3.3$ mSv).

SUBARACHNOID HEMORRHAGE AND CEREBRAL VASOSPASM

Cerebral vasospasm is a major cause of morbidity and mortality following aneurysmal SAH in patients who survive the initial hemorrhage and can be seen in about two-thirds of patients with aneurysmal SAH. The typical onset of cerebral vasospasm occurs three to five days after hemorrhage, with maximal narrowing on digital subtraction angiography at five to 14 days. Currently, the diagnosis of vasospasm and the management decisions rely on clinical examination, transcranial Doppler sonography, and digital subtraction angiography. Although

symptomatic vasospasm affects 20% to 30% of patients with aneurysmal SAH, not all patients with angiographic vasospasm manifest clinical symptoms, and the symptoms can be nonspecific. Also, patients do not always have both clinical and imaging findings of vasospasm. Due to these limitations, more accurate and reliable methods to detect cerebral vasospasm are being investigated.

BRAIN TUMORS

The current standard for tumor grading is a histopathologic assessment of tissue. Limitations of histologic assessment include sampling error due to regional heterogeneity and interobserver variation. These limitations can result in inaccurate classification and grading of gliomas. Because malignant brain tumors are characterized by neovascularity and increased angiogenic activity, perfusion imaging has been proposed as a method to assess tumor grade and prognosis. Also, perfusion imaging can be repeated and may help to assess the evolution of tumors and the treatment response. Traditionally, perfusion imaging of brain tumors has been performed with MRI, which can estimate tumor blood volume, blood flow, and permeability. More recently, CTP imaging has been investigated for glioma grading. Potential advantages, compared with magnetic resonance perfusion, include the wider availability, faster scanning times, and lower cost. CTP imaging may also be used to distinguish recurrent tumor from radiation necrosis.

REGULATORY STATUS

Several postprocessing software packages (e.g., Siemens' syngo® Perfusion-CT, GE Healthcare's CT Perfusion 4, Philips Medical System's Brain Perfusion Option) have been cleared for marketing by the U.S. Food and Drug Administration for use with a CT system to perform perfusion imaging. The software is being distributed with new CT scanners. Food and Drug Administration product code: JAK.

RELATED PROTOCOL

Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms)

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Burton KR, Dhanoa D, Aviv RI, et al. Perfusion CT for selecting patients with acute ischemic stroke for intravenous thrombolytic therapy. *Radiology*. Jan 2015;274(1):103-114. PMID 25243539.
2. Bivard A, Levi C, Krishnamurthy V, et al. Perfusion computed tomography to assist decision making for stroke thrombolysis. *Brain*. Jul 2015;138(Pt 7):1919-1931. PMID 25808369.

3. Schaefer PW, Souza L, Kamalian S, et al. Limited reliability of computed tomographic perfusion acute infarct volume measurements compared with diffusion-weighted imaging in anterior circulation stroke. *Stroke*. Feb 2015;46(2):419-424. PMID 25550366.
4. Liebeskind DS, Parsons MW, Wintermark M, et al. Computed tomography perfusion in acute ischemic stroke: is it ready for prime time? *Stroke*. Aug 2015;46(8):2364-2367. PMID 26159791.
5. Ma H, Campbell BCV, Parsons MW et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. *N. Engl. J. Med.*, 2019 May 9;380(19). PMID 31067369.
6. Garcia-Bermejo P, Calleja AI, Perez-Fernandez S, et al. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study. *Cerebrovasc Dis*. Jul 2012; 34(1):31-37. PMID 22759450.
7. Sztrihai LK, Manawadu D, Jarosz J, et al. Safety and clinical outcome of thrombolysis in ischaemic stroke using a perfusion CT mismatch between 3 and 6 hours. *PLoS One*. Oct 2011;6(10):e25796. PMID 22016775.
8. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*. Mar 12 2015;372(11):1009-1018. PMID 25671797.
9. Albers GW, Marks MP, Kemp S et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N. Engl. J. Med.*, 2018 Jan 25;378(8). PMID 29364767.
10. Nogueira RG, Jadhav AP, Haussen DC et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N. Engl. J. Med.*, 2017 Nov 14;378(1). PMID 29129157.
11. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. Jan 1 2015;372(1):11-20. PMID 25517348.
12. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*. Mar 12 2015;372(11):1019-1030. PMID 25671798.
13. Saver JL, Goyal M, Bonafe A, et al. Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. *Int J Stroke*. Apr 2015;10(3):439-448. PMID 25777831.
14. Borst J, Berkhemer OA, Roos YB, et al. Value of computed tomographic perfusion-based patient selection for intra-arterial acute ischemic stroke treatment. *Stroke*. Dec 2015;46(12):3375-3382. PMID 26542698.
15. Rai AT, Raghuram K, Domico J, et al. Pre-intervention triage incorporating perfusion imaging improves outcomes in patients undergoing endovascular stroke therapy: a comparison with the device trials. *J Neurointerv Surg*. Mar 2013;5(2):121-127. PMID 22345110.
16. Vanicek J, Cimflova P, Bulik M et al. Single-Centre Experience with Patients Selection for Mechanical Thrombectomy Based on Automated Computed Tomography Perfusion Analysis-A Comparison with Computed TomographyCT Perfusion Thrombectomy Trials. *J Stroke Cerebrovasc Dis*, 2019 Jan 19;28(4). PMID 30655040.
17. Lansberg MG, Christensen S, Kemp S, et al. Computed tomographic perfusion to Predict Response to Recanalization in ischemic stroke. *Ann Neurol*. Jun 2017;81(6):849-856. PMID 28486789.
18. Dankbaar JW, Horsch AD, van den Hoven AF, et al. Prediction of clinical outcome after acute ischemic stroke: the value of repeated noncontrast computed tomography, computed tomographic angiography, and computed tomographic perfusion. *Stroke*. Sep 2017;48(9):2593-2596. PMID 28716981.
19. van Seeters T, Biessels GJ, Kappelle LJ, et al. The prognostic value of CT angiography and CT perfusion in acute ischemic stroke. *Cerebrovasc Dis*. Oct 2015;40(5-6):258-269. PMID 26484857.
20. Greenberg ED, Gold R, Reichman M, et al. Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis. *AJNR Am J Neuroradiol*. Nov 2010;31(10):1853-1860. PMID 20884748.
21. Stecco A, Fabbiano F, Amatuzzo P et al. Computed tomography perfusion and computed tomography angiography in vasospasm after subarachnoid hemorrhage. *J Neurosurg Sci*, 2016 Apr 29;62(4). PMID 27124176.
22. Sanelli PC, Jou A, Gold R, et al. Using CT perfusion during the early baseline period in aneurysmal subarachnoid hemorrhage to assess for development of vasospasm. *Neuroradiology*. Jun 2011;53(6):425-434. PMID 20694461.

23. Cremers CH, van der Schaaf IC, Wensink E, et al. CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *J Cereb Blood Flow Metab.* Feb 2014; 34(2):200-207. PMID 24281744.
24. Sanelli PC, Ugorec I, Johnson CE, et al. Using quantitative CT perfusion for evaluation of delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. *AJNR Am J Neuroradiol.* Dec 2011;32(11):2047-2053. PMID 21960495.
25. Xyda A, Haberland U, Klotz E, et al. Brain volume perfusion CT performed with 128-detector row CT system in patients with cerebral gliomas: a feasibility study. *Eur Radiol.* Sep 2011;21(9):1811-1819. PMID 21573969.
26. Jain R. Perfusion CT imaging of brain tumors: an overview. *AJNR Am J Neuroradiol.* Oct 2011;32(9):1570-1577. PMID 21051510.
27. Ellika SK, Jain R, Patel SC, et al. Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. *AJNR Am J Neuroradiol.* Nov-Dec 2007;28(10):1981-1987. PMID 17893216.
28. Jain R, Ellika SK, Scarpace L, et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. *AJNR Am J Neuroradiol.* Apr 2008;29(4):694-700. PMID 18202239.
29. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Jun 2012;43(6):1711-1737. PMID 22556195.
30. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Mar 2013;44(3):870-947. PMID 23370205.
31. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Mar 2018;49(3):e46-e110. PMID 29367334.
32. Wintermark M, Sanelli PC, Albers GW, et al. Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. *AJNR Am J Neuroradiol.* Nov-Dec 2013;34(11):E117-127. PMID 23907247.
33. American College of Radiology, American Society of Neuroradiology, Society for Pediatric Radiology. ACR-ASNR-SPR practice parameter for the performance of computed tomography (CT) perfusion in neuroradiologic imaging. 2017; <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/ct-perfusion.pdf?la=en>. Accessed August 5, 2019.
34. American College of Radiology (ACR). ACR Appropriateness Criteria: Cerebrovascular Disease. 2016; <https://acsearch.acr.org/docs/69478/Narrative/>. Accessed August 5, 2019.
35. National Government Services, Inc. (Primary Geographic Jurisdiction 06 & K - Illinois, Minnesota, Wisconsin, Connecticut, New York - Entire State, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont) Local Coverage Article: Billing and Coding: Category III CPT® Codes (A56195), Revision Effective Date 01/01/2020.